PISCATAWAY, N.J., May 10, 2010 - Internationally recognized biology contract research organization GenScript USA Inc. has established an Antibody Drug Development Center to fulfill all the researchers’
http://www.genscript.com/
Antibody drug is among the most powerful forms of medication. There are intensive research and development activities being devoted to develop antibody drugs for numerous serious diseases, such as rheumatoid arthritis, multiple sclerosis, various cancers, etc.
GenScript’s antibody drug development center provides comprehensive services targeting every step of the antibody drug development process, which include hybridoma development andhybridoma stabilization which gives monoclonal antibodies and hybridomas the client need, antibody sequencing for information of the antibodies, chimeric antibody generation, antibody humanization to reduce immunogenicity of antibodies to human, affinity maturation that renders antibody with desired affinity for its function, epitope mapping, antibody/protein characterization to measure the affinity and thermostability of antibody and antigen, as well as antibody transient expression, antibody stable cell Line and antibody production services to generate sufficient amount of antibodies.
GenScript is a contract research organization (CRO) specialized in biological research and drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bioreagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has become a world-leading Biology CRO and the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China.
